Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2016 1
2017 1
2019 2
2020 1
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean d boschee[Author] (1 results)?
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM; SHARE-net Clinical Group. Thornhill JP, et al. Among authors: moschese d. N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323. Epub 2022 Jul 21. N Engl J Med. 2022. PMID: 35866746 Free article.
The Protective Role of Maternal Immunization in Early Life.
Cinicola B, Conti MG, Terrin G, Sgrulletti M, Elfeky R, Carsetti R, Fernandez Salinas A, Piano Mortari E, Brindisi G, De Curtis M, Zicari AM, Moschese V, Duse M. Cinicola B, et al. Among authors: moschese v. Front Pediatr. 2021 Apr 28;9:638871. doi: 10.3389/fped.2021.638871. eCollection 2021. Front Pediatr. 2021. PMID: 33996688 Free PMC article. Review.
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V, Amoruso GF, Malara G, De Pasquale R, Di Brizzi EV, Diluvio L, Bianchi L, Chiricozzi A, Di Guida A, Del Duca E, Moschese V, Di Lernia V, Dragoni F, Gruber M, Hansel K, Licari A, Manti S, Leonardi S, Mastorino L, Ortoncelli M, Provenzano E, Palermo A, Patella V, Peduto T, Pezzolo E, Piras V, Potestio L, Battista T, Satta R, Termine S, Palma P, Zangari P, Patruno C. Napolitano M, et al. Among authors: moschese v. Paediatr Drugs. 2022 Nov;24(6):671-678. doi: 10.1007/s40272-022-00531-0. Epub 2022 Aug 27. Paediatr Drugs. 2022. PMID: 36028611 Free PMC article.
Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EAS …
Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 w …
X-linked agammaglobulinemia (XLA):Phenotype, diagnosis, and therapeutic challenges around the world.
El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, Bousfiha AA, Cancrini C, Condino-Neto A, Dbaibo G, Derfalvi B, Dogu F, Edgar JDM, Eley B, El-Owaidy RH, Espinosa-Padilla SE, Galal N, Haerynck F, Hanna-Wakim R, Hossny E, Ikinciogullari A, Kamal E, Kanegane H, Kechout N, Lau YL, Morio T, Moschese V, Neves JF, Ouederni M, Paganelli R, Paris K, Pignata C, Plebani A, Qamar FN, Qureshi S, Radhakrishnan N, Rezaei N, Rosario N, Routes J, Sanchez B, Sediva A, Seppanen MR, Serrano EG, Shcherbina A, Singh S, Siniah S, Spadaro G, Tang M, Vinet AM, Volokha A, Sullivan KE. El-Sayed ZA, et al. Among authors: moschese v. World Allergy Organ J. 2019 Mar 22;12(3):100018. doi: 10.1016/j.waojou.2019.100018. eCollection 2019. World Allergy Organ J. 2019. PMID: 30937141 Free PMC article.
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999-2019).
Lougaris V, Pession A, Baronio M, Soresina A, Rondelli R, Gazzurelli L, Benvenuto A, Martino S, Gattorno M, Biondi A, Zecca M, Marinoni M, Fabio G, Aiuti A, Marseglia G, Putti MC, Agostini C, Lunardi C, Tommasini A, Bertolini P, Gambineri E, Consolini R, Matucci A, Azzari C, Danieli MG, Paganelli R, Duse M, Cancrini C, Moschese V, Chessa L, Spadaro G, Civino A, Vacca A, Cardinale F, Martire B, Carpino L, Trizzino A, Russo G, Cossu F, Badolato R, Pietrogrande MC, Quinti I, Rossi P, Ugazio A, Pignata C, Plebani A. Lougaris V, et al. Among authors: moschese v. J Clin Immunol. 2020 Oct;40(7):1026-1037. doi: 10.1007/s10875-020-00844-0. Epub 2020 Aug 15. J Clin Immunol. 2020. PMID: 32803625 Free PMC article.
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
Lombardi F, Belmonti S, Moschese D, Fabbiani M, Borghetti A, Ciccullo A, Visconti E, Di Giambenedetto S. Lombardi F, et al. Among authors: moschese d. HIV Res Clin Pract. 2022 Dec;23(1):28-36. HIV Res Clin Pract. 2022. PMID: 35758043
Subjects in the 3DR-group were matched with those in the 2DR-group for age, gender and type of anchor drug. Plasma levels of interleukin-6 (IL-6), I-FABP, D-dimer and C-reactive protein (CRP) were quantified by a microfluidic ultrasensitive ELISA assay at baseline and at 4 …
Subjects in the 3DR-group were matched with those in the 2DR-group for age, gender and type of anchor drug. Plasma levels of interleukin-6 ( …
Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort.
Cipriani F, Tripodi S, Panetta V, Perna S, Potapova E, Dondi A, Bernardini R, Caffarelli C, Casani A, Cervone R, Chini L, Comberiati P, De Castro G, Miraglia Del Giudice M, Dello Iacono I, Di Rienzo Businco A, Gallucci M, Giannetti A, Mastrorilli C, Moschese V, Pelosi S, Sfika I, Varin E, Villella V, Zicari AM, Brindisi G, Ricci G, Matricardi PM; Italian Pediatric Allergy Network (I-PAN). Cipriani F, et al. Among authors: moschese v. Pediatr Allergy Immunol. 2019 May;30(3):325-334. doi: 10.1111/pai.13036. Epub 2019 Apr 3. Pediatr Allergy Immunol. 2019. PMID: 30734368
The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, f …
The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, f …
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C, Iacopelli J, Pecoraro A, Spadaro G, Matucci A, Milito C, Vultaggio A, Agostini C, Cinetto F, Danieli MG, Gambini S, Marasco C, Trizzino A, Vacca A, De Mattia D, Martire B, Plebani A, Di Gioacchino M, Gatta A, Finocchi A, Licciardi F, Martino S, De Carli M, Moschese V, Azzari C. Canessa C, et al. Among authors: moschese v. Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7. Int J Immunopathol Pharmacol. 2017. PMID: 27927705 Free PMC article.
11 results